Latest News for MAJI
ORLANDO, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- Exousia Pro, Inc. (OTCPK: MAJI), a clinical-stage biotechnology leader specializing in proprietary exosome-based delivery systems, today announced the successful settlement of its outstanding litigation involving a former Director.
ORLANDO, Fla., March 05, 2026 (GLOBE NEWSWIRE) -- Exousia Pro, Inc. (OTCPK: MAJI), a clinical-stage biotechnology leader specializing in proprietary exosome-based delivery systems, is pleased to announce several pivotal corporate milestones aimed at enhancing shareholder value and expanding the company's commercial footprint.
ORLANDO, Fla., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Exousia Pro, Inc. (OTCID: MAJI), a clinical-stage biotechnology company specializing in proprietary exosome-based delivery systems, is pleased to announce a significant acceleration in its healthcare vertical with the execution of a third Letter of Intent (LOI) to acquire an established telehealth organization.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MAJI.
U.S. House Trading
No House trades found for MAJI.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.